Brief: MoonLake Immunotherapeutics Q3 EPS USD -1.1
05/11/2025 12:00
Nov 05 (Reuters) - MoonLake Immunotherapeutics Q3 net income USD -70.694 million.
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial